YSC 2015 Part 1: Update on Triple Negative Breast Cancer

These are a few of the Informational PowerPoint slides on the latest on Triple Negative Breast Cancer and Heredity Breast Cancer that was presented at Young Survival Coalition Summit 2015 that I attended in Houston.

How your tumor responds to neoadjuvant chemo?

Androgen receptor positive for possible treatment target?

Androgen negative receptors = Quadruple Negative Breast Cancer?

Clinical trials of PARP inhibitors in TNBC  BRCA +

PARP inhibitors benefit TNBC BRCA positive patients

Immunotherapy  breast cancer vaccine on the horizon?

Breast cancer genes linked to other cancer related diseases

Why genetic testing is important?

Genetic testing for hereditary risk

Extra screenings or preventative surgery?

In Triple-Negative Breast Cancer, Even Low-Androgen Tumors Respond to Anti-Androgen Therapy

Science Daily
Published February 24, 2015

"We're getting closer to being able to call some triple-negative breast cancers, androgen-receptor-positive breast cancers. And we may have to start referring to the remaining triple-negative breast cancers that are completely without androgen receptors as quadruple-negative breast cancers," Barton says.


Click link to full story:
http://www.sciencedaily.com/releases/2015/02/150224131201.htm

Anti-androgen therapy for triple-negative breast cancer may benefit lower-androgen tumors -- ScienceDaily

"Results showed that not only does anti-androgen receptor therapy reduce the ability of androgen-receptor-expressing triple-negative breast cancers to proliferate, migrate and invade, but for these cells, androgen receptor seems essential to survival. When Barton and colleagues blocked androgen receptor in these cells, the cells died."



Read full story: Anti-androgen therapy for triple-negative breast cancer may benefit lower-androgen tumors -- ScienceDaily

Clinical Trial Targets Androgen Receptor In Triple Negative Breast Cancer

In fact, 75 percent of all breast cancers and about 20 percent of triple negative cancers are positive for the androgen receptor. Blocking the androgen receptor may stop the growth of some triple negative breast cancers – these aggressive cancers for which chemotherapy, radiation, surgery and hope have long been the only treatments.

This week, after seeing, “no additional toxicities,” Elias expects an ongoing Phase I clinical trial of Enzalutamide for triple-negative breast cancers to flip to a Phase II trial – from proving safety to demonstrating results. In addition to the CU Cancer Center, the trial is being offered at Memorial Sloan-Kettering Cancer Center and the Karmanos Cancer Institute. 
http://www.coloradocancerblogs.org/clinical-trial-hits-new-target-in-war-on-breast-cancer/
(Click link to story)

Study Findings:Testosterone And Triple Negative Breast Cancer-Mayo Clinic

 “Importantly, while all normal breast tissue had androgen receptors, it was lost in the majority of patients with TNBC. Our data shows us that there is a definitive group of patients who may be sensitive to treatment directed against the androgen receptor." 

http://newsblog.mayoclinic.org/2012/03/22/mayo-clinic-tgen-study-role-testosterone-may-play-in-triple-negative-breast-cancer/
(click on link for full story)